Hormonal
High-dose omega-3 carboxylic acid formulation (4 g/d) does not reduce major adverse cardiovascular events in high-risk patients with atherogenic dyslipidemia compared to corn oil.
For high-risk patients with high triglycerides and low HDL, adding 4g/day of omega-3 carboxylic acid to statin therapy does not reduce the risk of heart attack, stroke, or cardiovascular death compared to a placebo. This specific formulation and dose should not be relied upon for cardiovascular risk reduction in this population.
Among statin-treated patients at high cardiovascular risk, the addition of omega-3 CA, compared with corn oil, to usual background therapies resulted in no significant difference in a composite outcome of major adverse cardiovascular events.
Why this rating
Double-blind, randomized, multicenter trial with 13,078 participants, terminated early due to futility.
Source
Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk
Stephen J. Nicholls et al. · JAMA · 2020
DOI 10.1001/jama.2020.22258
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →